retatrutide gip glp-1 glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The TRIUMPH-1 Phase 3 results

The semaglutide versus tirzepatide comparison provides foundational context for understanding how dual agonism differs from single agonism, which then extends to understanding how triple agonism differs from dual

Unlike older weight-loss drugs, retatrutide brings together three pathways in a single drug

First, it is a once-a-week injection, whereas liraglutide is once daily, so this may be more tolerable and less time-consuming for participants

Once a patient is active, chat in the portal is 24/7 with an AI front end that routes to a human if it cannot answer

This represents a paradigm shift from reactive treatment to proactive neurochemical modulation

By Distribution Channel By distribution channel, drug stores & retail pharmacies accounted for a share of 44.68% in 2025 due to widespread geographic accessibility, established prescription dispensing networks, and pharmacist-led patient counseling that supports chronic therapy continuation